Comparison of Delafloxacin Versus Ceftriaxone for the Treatment of Uncomplicated Gonorrhea
Public ClinicalTrials.gov record NCT02015637. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Comparative Evaluation of the Single-dose Efficacy of Oral Delafloxacin Versus the Single-dose Efficacy of an Intramuscular Injection of Ceftriaxone in Subjects With Uncomplicated Urogenital Gonorrhea
Study identification
- NCT ID
- NCT02015637
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Melinta Therapeutics, Inc.
- Industry
- Enrollment
- 460 participants
Conditions and interventions
Conditions
Interventions
- Delafloxacin Drug
- Ceftriaxone Drug
Drug
Eligibility (public fields only)
- Age range
- 15 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 22, 2014
- Primary completion
- Oct 31, 2014
- Completion
- Dec 9, 2014
- Last update posted
- Jun 19, 2018
2014
United States locations
- U.S. sites
- 25
- U.S. states
- 14
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Melinta 304 Study | Birmingham | Alabama | 35294 | — |
| Melinta 304 Study Site | Chula Vista | California | 90911 | — |
| Melinta 304 Study Site | La Mesa | California | 91942 | — |
| Melinta 304 Study Site | Los Angeles | California | 90069 | — |
| Melinta 304 Study Site | San Francisco | California | 94103 | — |
| Melinta 304 Study | Atlanta | Georgia | 30308 | — |
| Melinta 304 Study | Decatur | Georgia | 30033 | — |
| Melinta 304 Study Site | Indianapolis | Indiana | 46202 | — |
| Melinta 304 Study Site | New Orleans | Louisiana | 70112 | — |
| Melinta 304 Study Site | Omaha | Nebraska | 68114 | — |
| Melinta 304 Study Site | Las Vegas | Nevada | 89109 | — |
| Melinta 304 Study Site | Brooklyn | New York | 11203 | — |
| Melinta 304 Study | Brooklyn | New York | 11203 | — |
| Melinta 304 Study Site | New York | New York | 10018 | — |
| Melinta 304 Study Site | The Bronx | New York | 100461 | — |
| Melinta 304 Study Site | Durham | North Carolina | 27701 | — |
| Melinta 304 Study Site | Greensboro | North Carolina | 27405 | — |
| Melinta 304 Study Site | Cleveland | Ohio | 44108 | — |
| Melinta 304 Study Site | Columbus | Ohio | 43231 | — |
| Melinta 304 Study Site | Portland | Oregon | 97204 | — |
| Melinta 304 Study | Erie | Pennsylvania | 16507 | — |
| Melinta 304 Study Site | Philadelphia | Pennsylvania | 191007 | — |
| Melinta 304 Study Site | Pittsburgh | Pennsylvania | 15213 | — |
| Melinta 304 Study Site | Houston | Texas | 77011 | — |
| Melinta 304 Study Site | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02015637, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 19, 2018 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02015637 live on ClinicalTrials.gov.